peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, BMS  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
NCT04967430: TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Active, not recruiting
3
763
Canada
Peginterferon Lambda-1A, Placebo
University Health Network, Toronto
Sars-CoV2, Covid19
03/22
06/22
2021-003665-35: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

Not yet recruiting
3
150
Europe, RoW
Pegylated Interferon Lambda-1a, 361529, Solution for injection/infusion in pre-filled syringe
Eiger BioPharmaceuticals, Inc., EIGER BIOPHARMACEUTICALS, INC., Eiger BioPharmaceuticals, Inc.
Chronic Hepatitis Delta Virus (HDV) Infection, Chronic Hepatitis Delta Virus (HDV) Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Recruiting
3
7819
RoW
Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo
Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation
Covid19, SARS-Associated Coronavirus
06/24
07/24
LIMT-2, NCT05070364: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals
Hepatitis Delta Virus
06/24
01/25

Download Options